Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2025-12-27 @ 12:27 AM
Study NCT ID:
NCT00797550
Status:
TERMINATED
Last Update Posted:
2021-05-11
First Post:
2008-11-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Sponsor:
Vericel Corporation
Organization:
Study Overview
Official Title:
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated early for business reasons (not safety reasons).
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The hypothesis is that Aastrom TRC autologous bone marrow tissue "grafts" can be safely used to promote bone healing as part of a single level posterolateral spine fusion surgical procedure.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: